Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis.
Angiogenesis inhibition, long studied in the treatment of malignancies, has begun to emerge as a potential therapeutic approach in managing inflammatory arthritis, particularly rheumatoid arthritis. The growth of new vessels is required for the development of the rheumatoid pannus, which then leads to extensive synovial inflammation and joint destruction. Vascular endothelial growth factor is the best studied mediator of angiogenesis, and several therapies have been developed that specifically target this molecule. Several other angiogenesis mediators, such as the angiopoietin-TIE system, hypoxia inducible factor and integrin alpha(V)beta(3), as well as naturally occurring inhibitors of angiogenesis, are also being investigated as potential therapeutic targets. Additionally, there are a number of drugs, including paclitaxel, 2-methoxyestradiol and fumagillin analogs, that might have a role in inhibiting angiogenesis and, thus, in treating proliferative synovitis.
Rheumatology Fellowship Program, UCLA School of Medicine, University of California-Los Angeles, 1000 Veteran Avenue, Los Angeles, CA 90095, USA.
Dahlia
D
Lainer-Carr
Ernest
E
Brahn
D042682:Angiopoietins / Q000502:physiology; D003510:Cyclohexanes / Q000627:therapeutic use; D004852:Epoxy Compounds / Q000627:therapeutic use; D005231:Fatty Acids, Unsaturated; D006801:Humans; D051793:Hypoxia-Inducible Factor 1 / Q000037:antagonists & inhibitors / Q000502:physiology; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D042787:Receptor, TIE-2 / Q000037:antagonists & inhibitors; D012717:Sesquiterpenes / Q000627:therapeutic use; D013585:Synovitis / Q000188:drug therapy* / Q000503:physiopathology; D050257:Tubulin Modulators / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000502:physiology
D042682:Angiopoietins; D003510:Cyclohexanes; D004852:Epoxy Compounds; D005231:Fatty Acids, Unsaturated; D051793:Hypoxia-Inducible Factor 1; D039302:Integrin alphaVbeta3; C488724:PPI 2458; D012717:Sesquiterpenes; D050257:Tubulin Modulators; D042461:Vascular Endothelial Growth Factor A; C026211:fumagillin; D042787:Receptor, TIE-2; D014633:Valine; D000077609:O-(Chloroacetylcarbamoyl)fumagillol